Product Details :
| Feature | Details |
|---|---|
| Product Name | NUVALOP-ER 250 Tablets |
| Form | Extended-Release Tablets |
| Key Ingredients | Sodium Valproate + Valproic Acid (combined strength: 250 mg) |
| Core Benefits | Seizure control, mood stabilization, migraine prevention |
| Support Areas | Epilepsy, bipolar disorder, migraine prophylaxis |
| Recommended Usage | As prescribed by a neurologist or healthcare professional |
| Target Audience | Adults and children requiring controlled valproate therapy |
Composition: Divalproex Sodium Extended Release 250mg Packing: 10X10 Alu-Alu
Description : NUVALOP-ER 250 Tablets contain a combination of Sodium Valproate and Valproic Acid (total 250 mg) in an extended-release formulation, designed for the management of epilepsy, bipolar disorder, and migraine prevention. The ER (Extended Release) technology provides a stable drug release over time, reducing the frequency and severity of seizures and mood swings. NUVALOP-ER 250 is ideal for pediatric and adult patients requiring a lower initial dose or dose adjustment during therapy. It is effective, well-tolerated, and used under medical supervision.
